0HIY.LSE Atara Biotherapeutics, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0HIY.LSE undervalued?
Graham numberThe Graham number of Atara Biotherapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Atara Biotherapeutics, Inc. fundamental analysis
No fundamental analysis for Atara Biotherapeutics, Inc. yet.
Atara Biotherapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting…
Full company profileAtara Biotherapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Atara Biotherapeutics, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 20.3M | 63.6M | 8.57M | 129M | 121M | 2.29M |
| Gross Profit | -383K | -956K | -3.78M | -8.11M | -9.87M | 8.96M | 49.0M | -219M | 108M | 99.6M | 1.66M |
| Operating Income | -81.2M | -122M | -237M | -296M | -309M | -340M | -275M | -276M | -78.3M | 49.8M | -14.6M |
| EBITDA | -80.9M | -121M | -233M | -289M | -297M | -329M | -214M | -266M | -78.1M | 51.9M | -14.6M |
| Net Income | -79.0M | -119M | -231M | -291M | -307M | -340M | -228M | -276M | -85.4M | 32.7M | -18.0M |
| EPS | -2.73 | -3.40 | -5.02 | -5.67 | -4.15 | -3.63 | -2.24 | -4.99 | -11 | 2.57 | -1.19 |
| Balance Sheet | |||||||||||
| Total Assets | 264M | 218M | 392M | 343M | 588M | 468M | 376M | 166M | 109M | 20.2M | 21.0M |
| Total Liabilities | 10.2M | 39.9M | 53.0M | 52.2M | 126M | 189M | 250M | 265M | 206M | 58.7M | 58.0M |
| Shareholders' Equity | 254M | 178M | 339M | 291M | 462M | 280M | 127M | -99.2M | -97.3M | -38.5M | -37.0M |
| Cash & Short-term Investments | 256M | 166M | 310M | 259M | 501M | 371M | 243M | 51.7M | 42.6M | 8.48M | 9.87M |
| Total Debt | - | 500K | 738K | 15.7M | 15.0M | -27.5M | 71.7M | 60.5M | 84.1M | 9.35M | 51.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -60.0M | -87.5M | -180M | -236M | -181M | -221M | -270M | -193M | -68.7M | -50.9M | -12.8M |
| Capital Expenditure | 3.02M | 20.2M | 35.9M | 5.73M | 4.51M | 10.6M | 4.19M | 1.22M | 246K | 0.00 | 0.00 |
| Free Cash Flow | -63.0M | -108M | -216M | -241M | -185M | -231M | -275M | -194M | -69.0M | -50.9M | -12.8M |
| Ratios | |||||||||||
| ROE | -31.2% | -67.2% | -68.1% | -100.1% | -66.3% | -121.6% | -180.3% | - | - | - | - |
| ROA | -30.0% | -54.9% | -58.9% | -84.8% | -52.1% | -72.7% | -60.7% | -166.8% | -78.3% | 161.5% | -85.4% |
| Net Profit Margin | - | - | - | - | - | -1,672.3% | -359.1% | -3,220.9% | -66.2% | 27.1% | -783.5% |
| Debt to Equity | - | 0.00x | 0.00x | 0.05x | 0.03x | -0.10x | 0.57x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Atara Biotherapeutics, Inc. dividends
Atara Biotherapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.04:1 on Jun 20, 2024.
Who owns Atara Biotherapeutics, Inc.
- Insiders 16.80%
- Institutions 57.67%
- Public & others 25.53%
- Free float 4.62M
Atara Biotherapeutics, Inc. company profile
- Company name
- Atara Biotherapeutics, Inc.
- Ticker
- 0HIY.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320
- Phone
- 805 623 4211
- Website
- atarabio.com
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics, Inc. management
3- Dr. Anhco Nguyen Ph.D.President, CEO & Director · born 1973
- Mr. Kevin G. Sarney CPAInterim Chief Financial Officer · born 1965
- Mr. Jim SesicSenior Vice President of Regulatory Affairs